Flag of the European Union EU Clinical Trials Register Help

Clinical trials for huntington's disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    16 result(s) found for: huntington's disease. Displaying page 1 of 1.
    EudraCT Number: 2021-003453-28 Sponsor Protocol Number: SOMCT03 Start Date*: 2022-03-28
    Sponsor Name:SOM Innovation Biotech SA (SOM Biotech)
    Full Title: Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with chore...
    Medical condition: Huntington’s Disease with choreic movements.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003852-18 Sponsor Protocol Number: PTC518-CNS-002-HD Start Date*: 2022-06-02
    Sponsor Name:PTC Therapeutics, INC
    Full Title: A PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PTC518 IN SUBJECTS WITH HUNTINGTON'S DISEASE
    Medical condition: Huntington’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004988-22 Sponsor Protocol Number: ACR16 C008 Start Date*: 2008-01-11
    Sponsor Name:NeuroSearch Sweden AB
    Full Title: A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease
    Medical condition: Huntington's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) FR (Ongoing) ES (Ongoing) PT (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004360-22 Sponsor Protocol Number: Huntiam Start Date*: 2021-10-22
    Sponsor Name:Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
    Full Title: MULTI-TECHNICAL TEST ON THE USE OF COMBINED THERAPY OF THEMIN AND BIOTINE IN PATIENTS WITH HUNTINGTON'S DISEASE
    Medical condition: Huntington´s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003898-94 Sponsor Protocol Number: BN40955 Start Date*: 2019-03-07
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE
    Medical condition: Huntington's disease (HD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004556-15 Sponsor Protocol Number: WVE-003-001 Start Date*: 2021-03-12
    Sponsor Name:Wave Life Sciences UK Limited
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease
    Medical condition: Huntington's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) FR (Completed) DK (Completed) ES (Ongoing) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-001991-32 Sponsor Protocol Number: BN42489 Start Date*: 2023-01-13
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, BIOMARKERS, AND EFFICACY OF TOMINERSEN IN INDIVIDUALS WITH PRODROMAL AND EARLY MANIFEST HUNTINGT...
    Medical condition: Huntington's disease (HD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DE (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001314-19 Sponsor Protocol Number: VO659-CT01 Start Date*: 2023-04-25
    Sponsor Name:VICO Therapeutics B.V.
    Full Title: A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with sp...
    Medical condition: spinocerebellar ataxia types 1, 3 and Huntington’s disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 10010331 - Congenital, familial and genetic disorders 10057660 Spinocerebellar ataxia LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) IT (Prematurely Ended) DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002088-98 Sponsor Protocol Number: AN01.01.0012 Start Date*: 2005-11-07
    Sponsor Name:Amarin Neuroscience Ltd
    Full Title: Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease
    Medical condition: HUNTINGTON’S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    8.0 10010331 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Ongoing) AT (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001807-19 Sponsor Protocol Number: TV50717-CNS-30081 Start Date*: 2019-11-12
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP)
    Medical condition: Dyskinesia in cerebral palsy (DCP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10068804 Athetoid cerebral palsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Prematurely Ended) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004671-19 Sponsor Protocol Number: PDX 011 Start Date*: 2008-06-06
    Sponsor Name:Allos Therapeutics, Inc.
    Full Title: A Phase 2, Single-Arm Study of Pralatrexate in Patients with Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
    Medical condition: Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007294 Carcinoma bladder recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004242-42 Sponsor Protocol Number: J1S-MC-JV01 Start Date*: 2021-05-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor.
    Medical condition: Desmoplastic small round cell tumour (DSRCT)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064581 Desmoplastic small round cell tumour PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004243-23 Sponsor Protocol Number: J1S-MS-JV02 Start Date*: 2021-05-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with relapsed, Recurrent, or Refractory Synovial Sarcoma.
    Medical condition: Synovial Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002919-18 Sponsor Protocol Number: AC220-A-U202 Start Date*: Information not available in EudraCT
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, a...
    Medical condition: Relapsed or Refractory acute myeloid leukemia (AML) in subjects aged ≥1 month to ≤21 years with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutations following failure of fr...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    20.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    20.1 10022891 - Investigations 10076230 Fms-like tyrosine kinase 3 positive PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) FR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002916-34 Sponsor Protocol Number: ITCC-054/AAML1921 Start Date*: 2016-06-13
    Sponsor Name:Erasmus MC
    Full Title: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009700 CML LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IE (Completed) DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) DK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002116-14 Sponsor Protocol Number: CCTL019G2201J Start Date*: 2018-10-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive...
    Medical condition: Pediatric and young adult patients aged 1 to 25 years with first-line NCI high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) who are in CR1 with minimal residual disease (MRD) positive (MR...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    21.0 100000004864 10063621 Acute lymphoblastic leukaemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) DK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) NL (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Aug 03 08:45:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA